Cancer constitutes an enormous burden on society in more and less economically developed countries. An estimated 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide[@b1]. As one of the important established risk factors for cancer, environmental carcinogen like dioxin might contribute to its increasing prevalence[@b2][@b3]. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin) is the most toxic halogenated aromatic hydrocarbon[@b4], which is a widespread the environmental contaminant released by various sources of combustion, incineration, and chemical manufacturing[@b5][@b6]. This compound is extremely stable and thus accumulates in the food chain with a half-life of 7--9 years in humans[@b7][@b8]. In 1997, the International Agency for Research on Cancer (IARC) has classified it as a known human carcinogen (group 1) on the basis of animal studies and mechanistic information, but the epidemiology data was limited[@b2]. In 2012, the IARC illustrated the associations between TCDD and human cancers according to many observational studies[@b3], but these issues were not systematically reviewed and quantified by a meta-analysis. Molecular studies has proven that TCDD is a potent a carcinogen which could disrupt multiple endocrine pathways via aryl-hydrocarbon receptors (AhR) widely present in animals and humans[@b2][@b8][@b9].

As mentioned above, many epidemiological cohort studies and case-control studies have evaluated the association between TCDD/dioxin and cancer incidence and mortality[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40], but the results remained inconsistent. In addition, two previous meta-analyses reported the association between TCDD exposure and prostate cancer[@b41] and lung cancer[@b42], while another[@b43] reported the dose-response relationship for blood level of TCDD and cancer mortality based on 3 cohort studies. However, to date, no study has systematically analyzed the association between external exposure or blood level of TCDD and all cancer incidence and mortality. Thus, the aim of this study was to provide a systematically quantitative assessment of the association from an epidemiological point of view, and fill in gaps in the IARC deficiencies on this issue.

Materials and Methods
=====================

Data sources, search strategy and selection criteria
----------------------------------------------------

Systematic literature searches were conducted in PUBMED, EMBASE and Cochrane library (up to July 2015) to identify eligible studies. The following terms were used in the search procedure: ("dioxin" or "TCDD" or "Tetrachlorodibenzodioxin" or "2,3,7,8-Tetrachlorodibenzo-p-dioxin" or "Tetrachlorodibenzo-p-dioxin") AND ("cancer" or "tumor" or "tumour" or "carcinoma" or "neoplasm" or "sarcoma" or "melanoma" or "malignancy" or "leukemia" or "leukeamia" or "myeloma" or "lymphoma" or "adenoma"). Reports cited the references identified in this systematic review and relevant reviews were also searched to include potentially missed studies. Titles and abstracts were first scanned, and then full articles of potential eligible studies were reviewed. The retrieved studies were carefully examined to exclude potential duplicates or overlapping data. For duplicate reports, the ones with larger sample size, longer follow-up time and/or more detailed information were selected. This meta-analysis was designed, conducted and reported according to PRISMA and MOOSE statements[@b44][@b45].

Studies were eligible for inclusion if all the following criteria were fulfilled: (1) prospective or retrospective cohort studies and case-control studies evaluated the association between dioxin/TCDD and cancer incidence and mortality; (2) the odds ratio (OR), risk ratio (RR), standard incidence ratio (SIR) or standard mortality ratio (SMR) estimates and their 95% confidence intervals (95% CI) were given or sufficient data were available for evaluation; (3) articles as full papers in English were evaluated for eligibility. Studies reported the association between Agent Orange/herbicides and cancer incidence and mortality were excluded because the limitation of precise data on TCDD. For studies conducted in the same population, the criteria priority was established according to (1) whether the detailed information of different cancer subtypes and dioxin exposure level was provided or studies with a larger sample size and (2) the publication time. Reviews, meeting abstracts, notes, comments, editorials, and case reports were excluded because of the limited data.

Data extraction and quality assessment
--------------------------------------

Data extraction was carried out independently by two investigators (Drs. Xu JM and Ye Y). Discrepancies were resolved by a third investigator. The endpoints of this analysis were all cancer incidence and mortality as most of the included studies adopted, as well as site/type-specific cancers. The following information was extracted from each study: authors, year of publication, country of each study, study period, population characteristics (sample size, gender and age), and cancer subtypes. ORs (RRs, SIRs or SMRs) reflected the greatest degree of control for potential confounders were adopted in this meta-analysis. The quality of each study was assessed according to NEWCASTLE-OTTAWA quality assessment[@b46]. The total score ranges from 0 to 9, and a higher score indicates higher quality. Sensitivity analyses are further conducted according to the quality assessment results to explore the source of heterogeneity.

Data synthesis and statistical analysis
---------------------------------------

The primary meta-analyses were conducted to assess the association between external exposure and blood level of TCDD and all cancer incidence and mortality. Heterogeneity between individual studies was assessed by the chi-square test and I^2^ test; P ≤ 0.10 and/or I^2^ \> 50% indicates significant heterogeneity[@b47]. Summary ORs (RRs, SIRs or SMRs) and 95% CI were calculated using a random-effects model. The significance of the pooled ORs (RRs, SIRs or SMRs) were determined by Z test (p \< 0.05 was considered to be significant). Studies that reported results of a specific type of cancer but no data on all cancer were not pooled for all cancer analysis. Subgroup analyses were applied to explore source of heterogeneity and to evaluate potential effect of modification of variables including cancer subtype, exposure way and TCDD exposure reference category. In order to avoid bias and make the analysis more accurate, subgroup results were shown in pooled form if there were three or more studies for one subtype, otherwise, it was listed in an original form. Funnel plots were constructed and Begg's and Egger's tests were performed to assess the publication bias (*p* ≤ 0.10 was considered to be significant).

We analyzed the dose-response relationship using first-order, and second-order, and three-order fractional polynomial regression of the inverse variance-weighted data to estimate a curve of best fit. Best-fit curves were selected using decreased deviance compared with the reference model[@b48]. Comparisons of curves to determine best fit were done using a chi-square distribution. The average values within the blood TCDD categories were specified as the midpoint for bounded ranges, and 0.75 times the higher bound for the lowest (unbounded) range, and 1.25 times the lower bound for the highest (unbounded) range. RRs or SMRs (the ratio of observed to expected cancer deaths multiplied by 100) was the response measure used in these studies. All analyses were conducted using Stata software (version 12.0; StatCorp, College Station, TX, USA).

Results
=======

Study characteristics and data quality
--------------------------------------

After searching PUBMED, EMBASE and Cochrane library, 6446 articles were identified. 4437 articles were assessed after removing 2009 duplicate papers. Review of titles and abstracts resulted in exclusion of 4206 articles. For the remaining 231 articles, 163 were excluded for the following reasons: insufficient data (n = 60), foreign languages (n = 17), not on the right topic or targeted population (the outcomes of these studies were not cancer incidence or mortality, or the study interests were not dioxin) (n = 56), review articles (n = 14), meeting abstracts (n = 6), letters or comments (n = 10). 68 studies were included for further consideration and then 37 duplicate reports[@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66][@b67][@b68][@b69][@b70][@b71][@b72][@b73][@b74][@b75][@b76][@b77][@b78][@b79][@b80][@b81][@b82][@b83][@b84][@b85] from the same population were excluded. The detailed study selection methods for the same population are shown in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. Finally, a total of 31 studies[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40] were included for the meta-analysis, including 22 cohort studies and 9 case-control studies. There were different TCDD exposure ways as follow: occupational exposure, non-occupational exposure, industrial accidents, and soldiers exposed to herbicides used in Vietnam War. The reference categories also varied among different studies, some adopted the non-exposed population to calculate SIRs or SMRs (external reference), and others adopted the lowest exposure categories (internal reference). We pooled the RRs or SMRs of high-exposed versus non-exposed categories for external reference, and highest versus lowest categories for the internal reference. Of note, all the included case-control studies only provided data on specific cancer types but no combined data on all cancer, and these studies were only pooled for the subgroup analysis but not for the all cancer analysis in order to ensure the accuracy of the results. The selection process is shown in [Fig. 1](#f1){ref-type="fig"}, and the characteristics of the included studies are shown in [Table 1](#t1){ref-type="table"}. The exposure level and adjustment for confounders of included studies are shown in [Supplementary Table 2](#S1){ref-type="supplementary-material"}.

Among the included studies, ten[@b13][@b20][@b22][@b25][@b31][@b32][@b34][@b38][@b39][@b40] assessed the association between external exposure level of TCDD and cancer incidence. Eleven[@b10][@b11][@b12][@b15][@b16][@b17][@b18][@b20][@b21][@b29][@b30] evaluated the association between external exposure level of TCDD and cancer mortality. For blood and adipose tissue level of TCDD, seven[@b14][@b19][@b26][@b33][@b35][@b36][@b37] assessed cancer incidence and seven[@b14][@b16][@b23][@b24][@b27][@b28][@b29] evaluated cancer mortality. Ott *et al*.[@b14] reported the association between blood level of TCDD and both cancer incidence and mortality. Read *et al*.[@b20] reported the association between external exposure of TCDD and both cancer incidence and mortality. Steenland *et al*.[@b16] and Manuwald *et al*.[@b29] reported the association between both external exposure and blood level of TCDD and cancer mortality. The results of quality assessment were shown in the [Supplementary Table 3](#S1){ref-type="supplementary-material"}. The scores of most studies ranged from seven to nine (except for two studies got six points), which indicated the high quality of included studies and enhanced the reliability of the analysis. The PRISM checklist and flow diagram were shown in [Supplementary Tables 4](#S1){ref-type="supplementary-material"} and [5](#S1){ref-type="supplementary-material"}, respectively.

External exposure of TCDD and cancer incidence and mortality
------------------------------------------------------------

Ten studies involving 18,969 cancer cases and 3,155,159 participants assessed the association between external exposure of TCDD and cancer incidence, including five cohort studies and five case-control studies. The pooled RR of all cancer incidence of TCDD exposure level was 1.01 (95% CI: 0.97--1.06), indicating no significant association ([Fig. 2a](#f2){ref-type="fig"}). There was significant heterogeneity across the included studies (I^2^ = 73.5%, *p* \< 0.001), as shown in [Fig. 2a](#f2){ref-type="fig"}. Subgroup analysis was conducted according to cancer subtype, as shown in [Table 2](#t2){ref-type="table"}. The pooled RRs of different cancer types were all not significant, including breast cancer, Hodgkin's lymphoma, lymphatic leukemia, non-Hodgkin's lymphoma, and soft-tissue sarcoma. The results of subgroup analysis suggested the heterogeneity may be caused by special cancer types. Sensitivity analysis was also conducted to further explain the source of heterogeneity according to quality assessment results. After exclusion of the study[@b13] of the lowest score (six points), the pooled RR was 1.01(95% CI: 0.97--1.05), while the heterogeneity was not significantly changed (from I^2^ = 73.5% to I^2^ = 72.7%).

Eleven studies involving 9,122 cancer deaths and 691,326 participants assessed the association between external exposure of TCDD and cancer mortality. The pooled SMR of all cancer mortality of TCDD exposure level was 1.09 (95% CI: 1.01--1.19), indicating a significant positive association ([Fig. 2b](#f2){ref-type="fig"}). There was significant heterogeneity across the included studies (I^2^ = 90.8%, *p* \< 0.001), as shown in [Fig. 2b](#f2){ref-type="fig"}. Subgroup analyses for the association between external exposure of TCDD and cancer mortality were conducted according to cancer types and TCDD exposure ways, as shown in [Table 2](#t2){ref-type="table"}. The pooled SMRs of cancer mortality were significant in esophagus cancer (pooled SMR = 1.52, 95% CI: 1.09--2.13), larynx cancer (pooled SMR = 2.2, 95% CI: 1.61--3.02), kidney cancer (pooled SMR = 1.39, 95% CI: 1.08--1.78), non-Hodgkin's lymphoma (pooled SMR = 1.18, 95% CI: 1.01--1.37), myeloma (pooled SMR = 1.49, 95% CI: 1.03--2.15), soft-tissue sarcoma (pooled SMR = 1.60, 95% CI: 1.15--2.23), and occupational exposed population (pooled SMR = 1.25, 95% CI: 1.07--1.46). Subgroup analyses suggested that heterogeneity was partly influenced by cancer type and TCDD exposure way ([Table 2](#t2){ref-type="table"}). To further explore the potential impact of within-study heterogeneity, we also conducted sensitivity analyses according to the quality assessment results. After excluded the study[@b10] of the lowest score (six points), the pooled SMR was 1.10 (95% CI: 1.01--1.20), while the heterogeneity was not significantly changed (from I^2^ = 90.8% to I^2^ = 91.2%). The efficiency of the current sensitivity analysis was not able to provide evidence to further explain the source of heterogeneity.

Blood level of TCDD and cancer incidence and mortality
------------------------------------------------------

Seven studies comprising 837 cancer cases and 3,446 participants evaluated the association between blood of TCDD and cancer incidence, including three cohort studies and four case-control studies. The pooled RR of all cancer incidence for the highest versus lowest categories of TCDD exposure level was 1.57 (95% CI: 1.21--2.04), indicating a positive significant association ([Fig. 3a](#f3){ref-type="fig"}). The I^2^ and *p* value for heterogeneity across the included studies were 7.0% and 0.341 respectively, as shown in [Fig. 3a](#f3){ref-type="fig"}. Subgroup analysis was not conducted due to the limited data.

Seven studies involving 997 cancer deaths and 13,793 participants assessed the association between blood level of TCDD and cancer mortality. The pooled SMR of all cancer mortality for the highest versus lowest categories of TCDD exposure level was 1.45 (95% CI: 1.25--1.69), indicating a significant positive association ([Fig. 3b](#f3){ref-type="fig"}). There was no significant heterogeneity across the included studies (I^2^ = 4.7%, *p* = 0.394), as shown in [Fig. 3b](#f3){ref-type="fig"}. Subgroup analysis was conducted according to cancer type, exposure way and reference category. Two studies assessed the association between blood level of TCDD and non-Hodgkin's lymphoma, and the SMRs (95% CI) were 4.50 (1.20--11.50) and 1.36 (1.06--1.74), respectively. The results suggested a significant positive association, which was consistent with the results of higher exposure level of TCDD. However, the results should be treated cautiously considering the relatively small sample size (n = 11), and more studies were needed to validate it. The subgroup analyses also indicated that it was all significant for occupational exposed and non-occupational exposed population, and for external and internal reference category, which further verified the stability of the results.

Dose-response analysis was conducted based on five studies[@b14][@b16][@b23][@b24][@b29] according to the model of two-order fractional polynomial regression. RRs or SMRs using the low exposure group as the reference group were not appropriate for the dose-response analysis, which needs the RRs or SMRs relative to the normal background uncontaminated by occupational dioxin exposure[@b43]. Crump *et al*.[@b43] conducted a dose-response analysis in 2003 with only three studies. The raw data of Ott *et al*.[@b14] and Steenland *et al*.[@b16][@b77] was obtained by personal communication by the authors[@b43], thus we used these data extracted from Crump *et al*.[@b43] to improve the validity of our analysis. We adopted Manuwald *et al*.'s study[@b29] rather than Flesch-Janys *et al*.'s[@b63] for the Hamburg cohort since the former had a longer follow-up time. Cumulative serum lipid concentration (CSLC, ppt-years) was selected as the exposure metric to relate to risk, and the second-order fractional polynomial regression plot indicated a positive correlation between blood TCDD level and all cancer SMR, as shown in [Fig. 4a](#f4){ref-type="fig"}. After log transformation of TCDD dose, the curve showed a non-linear increasing trend ([Fig. 4b](#f4){ref-type="fig"}). The size of the circles in [Fig. 4](#f4){ref-type="fig"} represented the study sample size. The SMRs remained below 114.02 for serum TEQ dose from 316.23 ppt-years to 5141.62 ppt-years. For the TEQ dose of 1000, 10000, 100000 ppt-years, the SMRs with 95% CIs were 110.67(99.09--122.26), 119.82(105.79--133.23) and 167.68(141.77--194.21), respectively. With SMRs increased from 114.02 to 124.02, the TEQ dose increased form 5141.62 ppt-years to 14883.33 ppt-years.

Publication bias
----------------

Begg's funnel plots and Egger's linear regression test indicated no evidence of publication bias in the present study (TCDD external exposure and cancer incidence P~Begg~ = 0.755 and P~Egger~ = 0.245, and mortality P~Begg~ = 0.150 and P~Egger~ = 0.521; blood level of TCDD and cancer incidence P~Begg~ = 1.000 and P~Egger~ = 0.620, and mortality P~Begg~ = 0.711 and P~Egger~ = 0.834). The funnel plots were shown in [Supplementary Figures 1 to 4](#S1){ref-type="supplementary-material"}.

Discussion
==========

The current meta-analysis summarized the results of twenty-two cohort studies and nine case-control studies, including ten on external exposure level of TCDD and cancer incidence, eleven on external exposure level and cancer mortality, seven on blood level of TCDD and cancer incidence, and seven on blood level of TCDD and cancer mortality. The results indicated that higher external exposure level of TCDD was significantly associated with all cancer mortality but not all cancer incidence. For external exposure studies, the dioxin exposure ways, exposure quantification methods, reference categories, exposure level and adjustment for potential confounders differed greatly among included studies, which could cause heterogeneity and these results should be taken cautiously. Besides, there was a significantly positive association between higher blood level of TCDD and both all cancer incidence and mortality. The subgroup analysis for TCDD exposure mortality reported significant results for esophagus cancer, larynx cancer, kidney cancer, non-Hodgkin's lymphoma, myeloma, soft-tissue sarcoma and occupational exposed population. However, the IARC's review suggested that the evidence for specific cancers was strongest for lung cancer, soft-tissue sarcoma and non-Hodgkin's lymphoma[@b3]. The IARC's review listed the related publications, while they didn't distinguish the duplicated studies based on the same population and didn't provided quantitatively pooled results. Thus, the results of the current study may provide relatively more detailed indications on specific cancer types. Interestingly, the subgroup analysis also suggested consistence for increased mortality ratio of non-Hodgkin's lymphoma in both higher external exposure and blood level of TCDD, which may provide evidence on the precise carcinogenic potency of TCDD from an epidemiological point of view. The dose-response analysis showed an increasing trend of SMR with higher blood TEQ dose. For the TEQ dose of 1000, 10000, 100000 ppt-year, the SMRs were 110.67, 119.82 and 167.68, respectively.

The present meta-analysis provided epidemiological evidence for the carcinogenic potency of TCDD and the subgroup analysis showed specific cancer sites. Importantly, the consistent results for non-Hodgkin's lymphoma mortality of both external exposure and blood level of TCDD may indicate its specific effect on hematopoietic system. Although the sample size was relative small in the blood level of TCDD and non-Hodgkin's lymphoma mortality subgroup analysis, the results of the included two studies were both significant, independently. The SMRs and sample size of non-Hodgkin's lymphoma by Collins *et al*.[@b23] and Boers *et al*.[@b27] were 4.50 (1.2--11.5, n = 4) and 1.36 (1.06--1.74, n = 7), respectively, which suggested possibility that the association may be especially significant for non-Hodgkin's lymphoma. It has been reported by Hardell *et al*.[@b86] that exposure to phenoxy acids, chlorophenols and organic solvents may be a causative factor in malignant lymphoma as early as 1981. And based on decades of research, it has been realized that, exposure to dioxins, in particular TCDD could induce chloracne[@b87], and WHO has also classified it as a human carcinogen[@b3]. In consideration of the extensive sources, widespread trend and the strong toxicity of TCDD, the present results have considerable epidemiological and public health importance for humans. However its carcinogenic potential to humans and the mechanisms are not clearly demonstrated. It's commonly believed that AhR activation accounted for most biological properties of dioxins, including various physiological and developmental processes, tumor promotion, thymic involution, craniofacial anomalies, skin disorders and alterations in the endocrine, immunological and reproductive systems[@b50][@b88]. Furthermore, TCDD may also up-regulate drug-metabolizing enzymes, thus increasing the presence of highly reactive intermediates that form during metabolic activation and/or transformation of several key hormones[@b3]. Animal experiment also suggested that intraperitoneal injection of TCDD could cause increased incidence of lymphomas in male and female mice[@b89].

Determining the sources of heterogeneity is an important goal of meta-analysis. The heterogeneity of our study mainly existed in external exposure level of TCDD and all cancer incidence (I^2^ = 73.5%, p \< 0.001) and mortality (I^2^ = 90.8%, p \< 0.001). Subgroup analyses suggested that cancer subtype and dioxin exposure way can partially explain heterogeneity across the studies. Sensitivity analysis was also conducted according to the quality assessment results, while the efficiency was not able to provide evidence to further explain the source of heterogeneity. However, the heterogeneity caused by different TCDD exposure ways, quantification methods, reference categories (internal or external), lag time, background exposure levels and adjustment for confounders couldn't be fully quantified due to the limitation of individual participant data. The future research should pay more attention to the unity of survey methods and the standardization of the exposure reference category to control heterogeneity.

Our study has several strengths. First, we adopted the external exposure and blood level of TCDD to thoroughly assess the association between TCDD and cancer incidence and mortality. Second, subgroup analyses and dose-response analyses were applied, which further strengthened the conclusions and emphasized the TCDD effects on some specific cancer sites. Although the 2012 IARC monographs[@b3] evaluated the evidence in humans for the carcinogenicity of TCDD and made a list of cohort studies, these issues were not systematically reviewed and quantified by a meta-analysis. Thus, the current meta-analysis fill in gaps in the IARC deficiencies on this issue and it's of considerable interest and public health importance. In addition, no publication bias was observed, indicating that the pooled results should be unbiased.

However, the current analysis is restricted by several limitations. First, the number of studies involved in blood level of TCDD and all cancer incidence was relatively small, and thus some of the subgroup analyses were difficult to conduct. Second, in the dose-response analysis, the normal background uncontaminated by occupational dioxin exposure was different, and only McBride *et al*.[@b24] study provided the New Zealand background level of 3.9 ppt. We didn't add the background exposure level to our analysis for the limitation of original data. Third, the Steenland *et al*.[@b16] used a 15-year lag time, whereas no lag was used in other cohorts. Although the Crump *et al*.'s analysis[@b43] inferred that results based on cumulative exposure lagged 15 years should not differ greatly from those based on unlagged exposure, this could cause inaccuracy and heterogeneity. Thus, the individual participant data meta-analysis is needed to enhance future analysis. Fourth, the subgroup analysis for blood level of TCDD and all cancer mortality was limited in digestive system, respiratory system, lung cancer, prostate cancer and non-Hodgkin's lymphoma. More studies with precise data of different cancer types are warranted to support the effects of TCDD on other cancers.

In conclusion, our findings suggest that external exposure and blood level of TCDD were both significantly associated with all cancer mortality. Higher external exposure of TCDD may significantly increase the mortality rate of esophagus cancer, larynx cancer, kidney cancer, non-Hodgkin's lymphoma, myeloma, soft-tissue sarcoma and occupational exposure population. Of note, such relationship may be especially significant for non-Hodgkin's lymphoma.
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###### Characteristics of included studies.

  No.                    Study                                Country/cohort                                        Time period                   Exposure way          Exposure assessment                                                                                        Reference category                                                             Cancer types                                                                                                                                                                                                                                                                                                                                        Gender   No. of cancer cases/cohort or controls   Study quality   Age (years)          Duplicated reports
  ---------------------- ------------------------------------ ----------------------------------------------------- ----------------------------- --------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------- ---------------------------------------- --------------- -------------------- -------------------------------------------------------------------------------------------------------
  Cohort studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                         Exposure incidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  1                      Kogevinas[@b13]                      part of IARC[\*](#t1-fn1){ref-type="fn"}              1955--1988                    occupational          job records, company records and detailed company exposure questionnaires                                  External: SIR and SMR                                                          all cancer, breast cancer                                                                                                                                                                                                                                                                                                                           F        29/701                                   6               N/A                   
  2                      Read[@b20]                           New Zealand                                           1970--2001                    non-occupational      individual's recorded Territorial Authority for usual place of residence at death or cancer registration   External: New Plymouth population                                              all cancer, lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin's lymphoma, soft tissue sarcoma                                                                                                                                                                                                                                                    F/M      8013/375583                              8               N/A                   
  3                      Viel[@b22]                           French[\#](#t1-fn2){ref-type="fn"}                    1990--1999                    non-occupational      modelled ground-level concentrations                                                                       External: Isere population                                                     non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                                                              F/M      3974/2487274                             8               mean 61.49 ± 16.21    
  4                      Pesatori[@b25]                       Italy, Seveso                                         1977--1996                    industrial accident   measurements of TCDD soil levels                                                                           External: surrounding non-contaminated territory including 11 municipalities   All cancer, Esophagus, stomach, colon, rectum, liver, biliary tract, pancreas, lung, pleura, soft tissue sarcoma, melanoma, skin, breast, genito-urinary tract, ovary, prostate, testis, bladder, kidney, brain, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia                                                                       F/M      2122/218761                              8               0--74                Pesatori[@b72], Bertazzi[@b52], Pesatori[@b73]
  5                      Danjou[@b31]                         French, E3N cohort                                    1993--2008                    non-occupational      diet history questionnaire                                                                                 Internal: the lowest category                                                  breast cancer                                                                                                                                                                                                                                                                                                                                       F        3465/63830                               9               mean 52.73 ± 6.58     
                         Exposure mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  1                      Michalek[@b10]                       USA, vietnam veterans-AFSH                            1982--1987                    Vietnam war           physical Examination, Ranch Hands veterans                                                                 External: the comparison veterans                                              all cancer                                                                                                                                                                                                                                                                                                                                          M        12/2294                                  6               48.5                  
  2                      Zober[@b11]                          Germany-BASF Aktiengesellschaft                       1953--1987                    industrial accident   company records                                                                                            External: national mortality rate                                              all cancer, buccal cavity and pharynx, esophagus, stomach, colon, rectum, larynx, lung, bone, skin, prostate, bladder, leukemia                                                                                                                                                                                                                     F/M      23/247                                   8               mean 63.4             
  3                      Collins[@b12]                        USA, West Virginia, Monsanto company                  1949--1987                    industrial accident   work records and Internal Revenue Service Form                                                             External: local population mortality rate                                      all cancer, stomach, colorectal, liver and biliary, respiratory system, bone, skin, prostate, bladder, lymphatic and hematopoietic, soft-tissue sarcoma                                                                                                                                                                                             M        102/754                                  7               N/A                   
  4                      Kogevinas[@b15]                      IARC, 36cohorts[\$](#t1-fn3){ref-type="fn"}           1939--1992                    occupational          job records, company records and detailed company exposure questionnaires                                  External: SIR and SMR                                                          all cancer, buccal cavity and pharynx, esophagus, stomach, colon, rectum, liver and biliary, pancreas, peritoneum, nose and nasal sinuses, larynx, lung, bone, skin, prostate, kidney, testis, bladder, breast, cervix, endometrium and uterus, leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, brain, soft tissue sarcoma, thyroid   F/M      710/21863                                7               N/A                  Saracci[@b76], Kogevinas[@b67], Bueno de Mesquita[@b58], Kogevinas[@b13], Vena[@b79], Kogevinas[@b85]
  5                      Steenland[@b16]                      USA, NIOSH                                            1942--1993                    occupational          job records, job-exposure matrix and blood sample test                                                     External (US non-exposed people) and Internal (the lowest category)            all cancer, esophagus, stomach, colon, rectum, liver and biliary, pancreas, peritoneum, larynx, lung, prostate, kidney, bladder, lymphatic and hematopoietic, leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, brain and nervous system, connective tissue and soft tissue                                                             M        377/5172                                 7               N/A                  Fingerhut[@b61], Steenland[@b78], Salvan[@b75]
  6                      Revich[@b17]                         Russia                                                1983--1997                    non-occupational      food and soil concentration test                                                                           External: death rate in Samara Region                                          all cancer, intestine, stomach, colon, rectum, larynx, lung, bone, soft-tissue, breast, cervix, urinary organs, leukemia, lymphomas                                                                                                                                                                                                                 F/M      803/-                                    8               N/A                   
  7                      Bodner[@b18]                         USA-Michigan, Dow chemical company                    1940--1994                    occupational          job records and exposure score                                                                             External: other area workers with background exposure to dioxin                all cancer, lung, soft-tissue sarcoma, non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                       M        168/2187                                 7               N/A                  Cook[@b60], Ott[@b70], Bond[@b57], Ramlow[@b74]
  8                      Read[@b20]                           New Zealand                                           1970--2001                    non-occupational      individual's recorded Territorial Authority for usual place of residence at death or cancer registration   External: New Plymouth population                                              all cancer, lymphocytic leukemia, Hodgkin's disease, Non-Hodgkin's lymphoma, soft tissue sarcoma                                                                                                                                                                                                                                                    F/M      4235/375583                              8               N/A                   
  9                      Consonni[@b21]                       Italy, Seveso                                         1976--2001                    industrial accident   measurements of TCDD soil levels                                                                           External: surrounding non-contaminated territory including 11 municipalities   all cancer, stomach, colon, rectum, liver, biliary tract, pancreas, lung, soft tissue sarcoma, melanoma, breast, genito-urinary tract, ovary, prostate, bladder, kidney, brain, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia                                                                                                                 F/M      2278/278108                              8               0--74                Bertazzi[@b56], Bertazzi[@b55], Bertazzi[@b54], Bertazzi[@b53], Baccarelli[@b50]
  10                     Manuwald[@b29]                       Germany, Hamburg, Boehringer Ingelheim                1952--2007                    occupational          company records and blood or fat tissue samples                                                            External: Hamburg population                                                   all cancer, hypo pharynx, digestive organs, esophagus, stomach, colon, rectum, pancreas, larynx, lung, pleura, breast, prostate, kidney, bladder, hematopoietic system, non-Hodgkin's lymphoma                                                                                                                                                      F/M      291/1589                                 7               N/A                  Manz[@b68]
  11                     Wang[@b30]                           China                                                 1980--2005                    occupational          air sample concentration test                                                                              External: Chinese national mortality rates                                     all cancer, lung, liver, gastric                                                                                                                                                                                                                                                                                                                    F/M      121/3529                                 7               N/A                   
                         Blood incidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  1                      Ott[@b14]                            Germany, Ludwigshafen                                 1959--1992                    occupational          questionnaire and blood sample                                                                             External: West Germany population                                              all cancer, buccal cavity, digestive organs, stomach, colorectal, liver, gall bladder or bile duct, respiratory system, lung, prostate, bladder or kidney, lymphatic or hematopoietic tissue, skin                                                                                                                                                  M        47/243                                   7               N/A                   
  2                      Pavuk[@b19]                          USA, vietnam veterans                                 1982--2003                    Vietnam war           physical examination and blood sample                                                                      Internal: the lowest category                                                  all cancer, all SEER sites, digestive system, respiratory system, melanoma, basal or squamous cell, prostate                                                                                                                                                                                                                                        M        402/1482                                 8               mean 63.7            Ketchum[@b66], Akhtar[@b49], Pavuk[@b71], Michalek[@b69]
  3                      Warner[@b26]                         Italy, Seveso, SWHS cohort                            I:1976--1996, II:1997--2009   industrial accident   interview, physical examination and blood sample                                                           Internal: the lowest category                                                  all cancer, breast cancer                                                                                                                                                                                                                                                                                                                           F        66/981                                   9               0--40                Warner[@b80]
                         Blood mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  1                      Ott[@b14]                            Germany, Ludwigshafen                                 1959--1992                    occupational          questionnaire and blood sample                                                                             External: West Germany population                                              all cancer, digestive organs, respiratory system, prostate, bladder or kidney, lymphatic or hematopoietic tissue                                                                                                                                                                                                                                    M        31/243                                   7               N/A                  Zober[@b11]
  2                      Steenland[@b16]                      USA, NIOSH                                            1942--1993                    occupational          job records, job-exposure matrix and blood sample test                                                     External (US non-exposed people) and Internal (the lowest category)            all cancer, lung cancer                                                                                                                                                                                                                                                                                                                             M        256/5172                                 8               N/A                  Steenland[@b77], Cheng[@b59]
  3                      Collins[@b23]                        USA, Michigan                                         1937--1980                    occupational          job records and blood sample test                                                                          External (US population) and Internal (the lowest category)                    all cancer, lung, prostate, kidney, non-Hodgkin's lymphomas                                                                                                                                                                                                                                                                                         M        94/773                                   8               mean 31.1             
  4                      McBride[@b24]                        New Zealand                                           1969--2004                    occupational          job records and blood sample test                                                                          External (New Zealand population) and internal (the lowest category)           all cancer, digestive organs, lung, soft-tissue sarcoma, lymphatic and hematopoietic tissue, non-Hodgkin's lymphoma                                                                                                                                                                                                                                 F/M      61/1599                                  8               mean 52.9             
  5                      Boers[@b27]                          Netherlands, Dutch cohort                             1955--2006                    occupational          blood sample test and predictive model                                                                     Internal (background exposure level as reference)                              all cancer, digestive organs, stomach, pancreas, respiratory system, lung, skin, genital and urinary cancer, prostate, bladder, kidney, lymphatic and hematopoietic cancer, non-Hodgkin's lymphoma, leukemia                                                                                                                                        M        192/2056                                 8               N/A                  Heederik[@b64], Hooiveld[@b65]
  6                      Lin[@b28]                            USA, NHANES                                           1999--2006                    non-occupational      blood sample test                                                                                          Internal (the lowest category)                                                 all cancer                                                                                                                                                                                                                                                                                                                                          F/M      72/2361                                  8               \>40                  
  7                      Manuwald[@b29]                       Germany, Hamburg                                      1952--2007                    occupational          company records and blood or fat tissue samples                                                            External: Hamburg population                                                   all cancer, digestive organs, respiratory system, breast cancer                                                                                                                                                                                                                                                                                     F/M      291/1589                                 7               N/A                  Flesch-Janys[@b62], Bencher/[@b51], Flesch-Janys[@b63]
  Case-control studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                         Exposure incidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  1                      Hardell[@b32]                        Sweden                                                1970--1986                    non-occupational      structured questionnaire and work history                                                                  Internal (unexposed)                                                           soft-tissue sarcoma                                                                                                                                                                                                                                                                                                                                 M        434/948                                  6               25--80               Hardell[@b81], Eriksson[@b82], Hardell[@b83], Eriksson[@b84]
  2                      Floret[@b34]                         France, Besançon                                      1980--1995                    non-occupational      modeled ground-level according to meteorological conditions                                                Internal (the lowest category)                                                 non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                                                              F/M      222/2220                                 6               median 66             
  3                      Zambon[@b38]                         Italy, Venice                                         1990--1996                    non-occupational      survey of the incinerators and industrial sources of airborne dioxin                                       Internal (the lowest category)                                                 sarcoma                                                                                                                                                                                                                                                                                                                                             F/M      172/405                                  6               N/A                   
  4                      Viel[@b39]                           France, Besançon                                      1996--2002                    non-occupational      modeled ground-level according to meteorological conditions                                                Internal (the lowest category)                                                 breast cancer                                                                                                                                                                                                                                                                                                                                       F        434/2170                                 6               \>20                  
  5                      Villeneuve[@b40]                     Eight European countries[‖](#t1-fn4){ref-type="fn"}   1995--1997                    occupational          structured questionnaire and work history                                                                  Internal (the lowest category)                                                 male breast cancer                                                                                                                                                                                                                                                                                                                                  M        104/1901                                 6               35--70                
                         Blood and adipose tissue incidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  1                      Hardell[@b33]                        Sweden                                                1994--1997                    non-occupational      adipose tissue sample test                                                                                 Internal (the lowest category)                                                 non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                                                              NA       33/39                                    7               NA                    
  2                      Tuomisto[@b35]                       Finland                                               1997--1999                    non-occupational      fat sample test and questionnaire                                                                          Internal (the lowest category)                                                 soft-tissue sarcoma                                                                                                                                                                                                                                                                                                                                 F/M      110/227                                  7               15.0--91.1            
  3                      De Roos[@b36]                        US, NCI; SEER, the parent study                       1998--2000                    non-occupational      blood sample test                                                                                          Internal (the lowest category)                                                 non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                                                              F/M      100/100                                  5               20--74                
  4                      Reynolds[@b37]                       US                                                    mid-1990s                     non-occupational      adipose tissue sample test and questionnaire                                                               Internal (the lowest category)                                                 breast cancer                                                                                                                                                                                                                                                                                                                                       F        79/52                                    6               mainly 40--59         

IARC: The International Agency for Research on Cancer.

E3N: Etude Epidémiolog ique auprès de femmes de la Mutuelle Générale de l'Education Nationale.

AFSH: air force health study.

NIOSH: National Institute for Occupational Safety and Health.

SWHS: the Seveso Women's Health Study.

NHANES: National Health and Nutrition Examination Survey.

F: female, M: male, N/A: not available.

Study quality was judged on the basis of the Newcastle-Ottawa Scale (1--9 stars).

^\*^Austria, Denmark, Finland, Italy, Netherlands, New Zealand, and Sweden.

^\#^Four administrative departments, Isère, Bas-Rhin, Haut-Rhin and Tarn.

^\$^Australia, Austria, Canada, Denmark, Finland, Italy, the Netherlands, New Zealand, Sweden, UK, Germany, USA.

^‖^Denmark, France, Germany, Italy, Sweden, Latvia, Portugal and Spain.

###### Subgroup analyses of the association between TCDD and cancer incidence and mortality.

  Categories               Classification                                  Study number                   No. of cases                                 RR or SMR (95% CI)                Heterogeneity        Study       
  ------------------------ ---------------------------------------------- -------------- ----------------------------------------------- ---------------------------------------------- --------------- ----------------- -----------------
  Exposure incidence                                                                                                                                                                                                      
   cancer type             breast cancer                                        3                             3768                                      0.99(0.93--1.06)                     9.30%            0.356                
  Hodgkin's lymphoma       2                                                    49                      1.13(0.83--1.54)                                      ---                             ---          Read[@b20]     
  26                       1.42(0.93--2.18)                                    ---                             ---                                       Pesatori[@b25]                                                   
  lymphatic leukemia       2                                                   104                      1.35(0.93--1.97)                                      ---                             ---          Read[@b20]     
  13                       0.83(0.46--1.48)                                    ---                             ---                                       Pesatori[@b25]                                                   
  non-Hodgkin's lymphoma   4                                                   4263                     1.09(0.92--1.30)                                     65.80%                          0.001                        
  soft-tissue sarcoma      4                                                   105                      1.37(0.97--1.93)                                     48.70%                          0.041                        
  Exposure mortality                                                                                                                                                                                                      
   cancer type             buccal cavity and pharynx                            2                              22                                       1.30(0.82--1.97)                      ---              ---         Kogevinas[@b15]
  11                       2.17(1.08--3.87)[\*](#t2-fn1){ref-type="fn"}        ---                             ---                                       Manuwald[@b29]                                                   
  esophagus                3                                                    44        1.52(1.09--2.13)[\*](#t2-fn1){ref-type="fn"}                       9.10%                           0.333                        
  stomach                  7                                                   433                      1.02(0.82--1.27)                                     68.10%                          0.001                        
  colorectal               7                                                   453                      1.05(0.94--1.19)                                     20.10%                          0.214                        
  colon                    5                                                   298                      0.97(0.86--1.09)                                     0.00%                           0.532                        
  rectum                   5                                                   154                      1.18(0.97--1.44)                                     25.10%                          0.238                        
  liver and biliary        5                                                   212                      1.01(0.79--1.30)                                     0.00%                           0.046                        
  pancreas                 4                                                   139                      0.93(0.78--1.11)                                     0.00%                           0.719                        
  peritoneum               2                                                    5                       2.19(0.45--6.41)                                      ---                             ---        Steenland[@b16]  
  3                        1.23(0.40--2.80)                                    ---                             ---                                      Kogevinas[@b15]                                                   
  larynx                   4                                                    45        2.20(1.61--3.02)[\*](#t2-fn1){ref-type="fn"}                       0.00%                           0.563                        
  trachea/lung             8                                                   1190                     1.21(0.89--1.65)                                     95.20%                         \<0.001                       
  prostate                 5                                                   172                      1.14(0.97--1.34)                                     0.00%                           0.830                        
  kidney                   4                                                    90        1.39(1.08--1.78)[\*](#t2-fn1){ref-type="fn"}                       16.60%                          0.309                        
  bladder                  5                                                   117                      1.73(0.95--3.18)                                     89.00%                         \<0.001                       
  Hodgkin's disease        4                                                    43                      1.35(0.97--1.88)                                     0.00%                           0.895                        
  non-Hodgkin's lymphoma   6                                                   239        1.18(1.01--1.37)[\*](#t2-fn1){ref-type="fn"}                       20.10%                          0.235                        
  myeloma                  3                                                    50        1.49(1.03--2.15)[\*](#t2-fn1){ref-type="fn"}                       24.80%                          0.256                        
  leukemia                 5                                                   156                      1.14(0.96--1.35)                                     0.00%                           0.464                        
  skin                     2                                                    9                       0.89(0.36--2.18)                                      ---                             ---        Kogevinas[@b15]  
  3                        0.85(0.49--1.48)                                    ---                             ---                                       Consonni[@b21]                                                   
  brain nervous system     3                                                    57                      0.91(0.69--1.20)                                     0.00%                           0.418                        
  bone                     2                                                    2                       5.00(0.60--18.1)                                      ---                             ---         Collins[@b12]   
  3                        1.08(0.22--3.14)                                    ---                             ---                                      Kogevinas[@b15]                                                   
  soft-tissue sarcoma      6                                                    46        1.60(1.15--2.23)[\*](#t2-fn1){ref-type="fn"}                       0.00%                           0.550                        
  breast                   4                                                   234                      1.27(0.78--2.06)                                     87.80%                         \<0.001                       
  endometrium and uterus   2                                                    3                       3.41(0.70--9.96)                                      ---                             ---        Kogevinas[@b15]  
  43                       0.99(0.44--2.24)                                    ---                             ---                                       Consonni[@b21]                                                   
   exposure way            non-occupational                                     2                              803                                      1.28(0.65--2.52)                      ---              ---          Revich[@b17]
  4235                     1.00(0.97--1.04)                                    ---                             ---                                         Read[@b20]                                                     
  occupational             5                                                   1667       1.25(1.07--1.46)[\*](#t2-fn1){ref-type="fn"}                       78.30%                          0.001                        
  industrial accident      3                                                   2405                     1.02(0.91--1.14)                                     44.80%                          0.093                        
  Vietnam war              1                                                    12                      0.70(0.30--1.10)                                      ---                             ---        Michalek[@b10]   
  Serum mortality                                                                                                                                                                                                         
   cancer type             digestive organs                                     4                              82                                       1.22(0.88--1.69)                    44.00%            0.147                
  respiratory system       3                                                    82                      1.25(0.86--1.81)                                     57.50%                          0.095                        
  lung                     4                                                    74                      0.99(0.86--1.15)                                     0.00%                           0.450                        
  prostate                 2                                                    4                       1.40(0.40--3.60)                                      ---                             ---         Collins[@b23]   
  14                       1.08(0.79--1.49)                                    ---                             ---                                        Boers[@b27]                                                     
  non-Hodgkin's lymphoma   2                                                    4         4.50(1.20--11.50)[\*](#t2-fn1){ref-type="fn"}                       ---                             ---         Collins[@b23]   
  7                        1.36(1.06--1.74)[\*](#t2-fn1){ref-type="fn"}        ---                             ---                                        Boers[@b27]                                                     
   exposure way            non-occupational                                     1                              72                         2.34(1.08--5.08)[\*](#t2-fn1){ref-type="fn"}        ---              ---            Lin[@b28]
  occupational             4                                                   925        1.43(1.23--1.66)[\*](#t2-fn1){ref-type="fn"}                       0.00%                           0.442                        
   reference category      external                                             5                              733                        1.39(1.18--1.63)[\*](#t2-fn1){ref-type="fn"}       0.00%            0.458                
  internal                 2                                                   192        1.80(1.16--2.82)[\*](#t2-fn1){ref-type="fn"}                        ---                             ---          Boers[@b27]    
  72                       2.34(1.08--5.08)[\*](#t2-fn1){ref-type="fn"}        ---                             ---                                         Lin[@b28]                                                      

--- Could not be calculated.

^\*^Significant association was indicated, statistical z test: p \< 0.05.

[^1]: These authors contributed equally to this work.
